Teladoc Health, Inc.
TDOC · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 0.18 | -0.04 | -0.20 |
| FCF Yield | 7.14% | 5.88% | 0.95% | 3.58% |
| EV / EBITDA | -47.29 | 705.69 | -198.56 | 157.63 |
| Quality | ||||
| ROIC | -2.07% | -1.76% | -3.30% | -1.55% |
| Gross Margin | 70.12% | 69.85% | 68.73% | 70.50% |
| Cash Conversion Ratio | -2.01 | -2.80 | -0.17 | -1.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.67% | 0.15% | 1.10% | 2.20% |
| Free Cash Flow Growth | 7.56% | 583.42% | -76.55% | -28.81% |
| Safety | ||||
| Net Debt / EBITDA | -8.69 | 132.89 | -43.90 | 24.30 |
| Interest Coverage | -11.48 | -12.16 | -20.92 | -7.04 |
| Efficiency | ||||
| Inventory Turnover | 4.69 | 4.99 | 5.18 | 4.95 |
| Cash Conversion Cycle | 24.37 | 25.64 | 26.89 | 33.86 |